A5055294177- Chronic Kidney Disease and Diabetes
- Renin-Angiotensin System Studies
- Advanced Glycation End Products research
- Blood Pressure and Hypertension Studies
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Nitric Oxide and Endothelin Effects
- Hormonal Regulation and Hypertension
- Renal Diseases and Glomerulopathies
- Atherosclerosis and Cardiovascular Diseases
- Peroxisome Proliferator-Activated Receptors
- Birth, Development, and Health
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Cholesterol and Lipid Metabolism
- Apelin-related biomedical research
- Liver Disease Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Connective Tissue Growth Factor Research
- Natural Antidiabetic Agents Studies
- Pharmacology and Obesity Treatment
- Lipoproteins and Cardiovascular Health
- Diet and metabolism studies
- Chronic Myeloid Leukemia Treatments
Monash University
2004-2020
Baker Heart and Diabetes Institute
2007-2018
Maastricht University
2015
University of Southern Denmark
2015
The University of Queensland
2014
University of Freiburg
2014
Osaka University
2014
The Alfred Hospital
2010
Austin Health
2004-2009
The Heart Research Institute
2003-2006
Advanced glycation end product (AGE) formation may contribute to the progression of atherosclerosis, particularly in diabetes. The present study explored atherosclerosis streptozotocin-induced diabetic apolipoprotein E–deficient (apoE−/−) mice that were randomized (n = 20) receive for 20 weeks no treatment, AGE cross-link breaker ALT-711, or inhibitor aminoguanidine (AG). A sixfold increase plaque area with diabetes was attenuated by 30% ALT-711 and 40% AG-treated mice. Regional distribution...
Background — Atherosclerosis is a major complication of diabetes, but the mechanisms by which diabetes promotes macrovascular disease have not been fully delineated. Although several animal studies demonstrated that inhibition ACE results in decrease development atherosclerotic lesions, information about potential benefits these agents on complex and advanced lesions as observed long-term lacking. The aim this study was to evaluate whether treatment with inhibitor perindopril affects...
Recent clinical studies have suggested a major protective role for the antioxidant enzyme glutathione peroxidase-1 (GPx1) in diabetes-associated atherosclerosis. We induced diabetes mice deficient both GPx1 and apolipoprotein E (ApoE) to determine whether this is merely an association or has direct effect on atherosclerosis.ApoE-deficient (ApoE-/-) ApoE/GPx1 double-knockout (ApoE-/- GPx1-/-) were made diabetic with streptozotocin aortic lesion formation, atherogenic pathways assessed after...
Transforming growth factor-beta (TGF-beta) and the renin-angiotensin system (RAS) have both been implicated in pathogenesis of glomerulosclerosis diabetic kidney disease. However, tubulointerstitial pathology may also be an important determinant progressive renal dysfunction nephropathy. In present study, we investigated injury, TGF-beta1 expression, effect blocking RAS by inhibition ACE. We randomized 36 male SD rats to control groups. Diabetes was induced 24 administration streptozotocin;...
It remains controversial whether specific blockade of the renin-angiotensin system confers superior antiatherosclerotic effects over other antihypertensive agents in diabetes. Therefore, aim this study was to compare equihypotensive doses angiotensin II subtype 1 (AT1) receptor blocker irbesartan with calcium antagonist amlodipine on diabetes-induced plaque formation apolipoprotein E (apoE)-null mouse and explore molecular cellular mechanisms linked vascular protection.Diabetes induced by...
This study describes patterns of progression albuminuria and renal function in a subgroup 40 patients from total cohort 211 diabetic (118 type I, 93 II) followed over period 8–14 years. Forty (18 with I diabetes, 22 II diabetes) showed progressive increases albumin excretion rate (AER) and/or decreases creatinine clearance (CC) during the period. Of these, AER alone increased 15 patients, CC decreased 13 12 similar distribution each group. 28 who an increase albuminuria, at annual 30–40%,...
Diabetes is associated with accelerated atherosclerosis, the major factor contributing to increased mortality and morbidity in diabetic population. The molecular mechanisms by which diabetes promotes atherosclerosis are not fully understood. Platelet-derived growth has been shown play a role pathology of vascular diseases, but whether it plays remains unknown. aims this study were assess platelet-derived factor-dependent pathways involved development diabetes-induced determine effects...
Hyperlipidemia not only may be relevant to cardiovascular disease in diabetes but also play a role the development and progression of diabetic nephropathy. Furthermore, there is increasing evidence that advanced glycation end products (AGE) an important renal disease. The objectives this study were first characterize injury apolipoprotein E knockout (apo E-KO) mice second explore AGE model. Diabetes was induced by injection streptozotocin 6-wk-old apo E-KO mice. Diabetic animals received no...
Recent studies have demonstrated a role for thiazolidinediones in attenuating atherosclerosis. However, these were performed insulin-resistant animal models association with reductions insulin and glucose levels. To assess the vascular effects of thiazolidinediones, independent their metabolic effects, we observed effect rosiglitazone on diabetes-associated atherosclerosis model insufficiency.Control diabetic apolipoprotein E-deficient mice received or placebo. Diabetic 3-fold increase...
OBJECTIVE—Diabetic subjects have a high prevalence of hypertension, increased total body exchangeable sodium levels, and an impaired ability to excrete load. This study assessed the effect dietary restriction on efficacy losartan in hypertensive with type 2 diabetes albumin excretion rates 10–200 μg/min. RESEARCH DESIGN AND METHODS—In this study, 20 were randomized 50 mg/day (n = 10) or placebo 10). Drug therapy was given two 4-week phases separated by washout period. In last weeks each...
To evaluate the role of nitric oxide (NO) in diabetic hyperfiltration, renal hemodynamic changes and urinary excretion NO2/NO3 response to NO inhibitor nitro-L-arginine methyl ester (L-NAME) NO-donating agent glyceryl trinitrate (GTN) were investigated conscious streptozocin-induced (D) age-matched control (C) rats. In all experiments, D rats demonstrated increased glomerular filtration rate (GFR), plasma flow (RPF), polyuria, an sodium when compared with C An intravenous bolus low-dose...
In the diabetic kidney, clinical as well experimental observations have shown an upregulation of growth factors such PDGF. These studies, however, were not designed to address whether PDGF is merely a manifestation renal injury or plays active role in pathophysiology nephropathy. The objectives this study first assess PDGF-dependent pathways are involved development nephropathy and second determine effects receptor antagonism on disorder associated molecular cellular processes. This used...
Atherosclerosis is driven by inflammatory reactions that are shared with the innate immune system. Toll-like receptor-9 (TLR9) an intracellular pattern recognition receptor of system currently under clinical investigation as a therapeutic target in diseases. Here, we investigated whether TLR9 has role development atherosclerosis apolipoprotein E-deficient (ApoE(-/-)) mice.Newly generated double-knockout ApoE(-/-):TLR9(-/-) mice and control ApoE(-/-) were fed high-fat diet from 8 weeks...
We explored the relative roles of suppression angiotensin II and prevention bradykinin degradation in mediating renoprotective effects ACE inhibitors experimental diabetic nephropathy. Over a 24-week period, we studied male Sprague-Dawley control rats treated with inhibitor ramipril, II-AT1 receptor antagonist valsartan, bradykinin-B2 HOE 140 (icatibant), combination ramipril icatibant. Serial measurements urinary albumin excretion, blood pressure, glycated hemoglobin were performed monthly....
Backgound. Peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists are widely used in diabetes. In addition to their effects on lipid glucose homeostasis, these agents have been postulated independent renoprotective actions. the current study, we assess efficacy of PPAR-α agonist, gemfibrozil, agonist rosiglitazone non-thiazolidinedione PPAR-α/γ coagonist, compound 3q, kidney structure function streptozotocin-treated apolipoprotein E knockout mice.
Streptozotocin (STZ) diabetes was induced in spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. Body weight, blood pressure, renal function, glycaemic control proteinuria were assessed monthly for 32 weeks. At weeks, the animals killed glomerular basement membrane (GBM) thickness fractional mesangial volume measured There no significant difference function between diabetic SHR WKY. Diabetic showed an earlier larger rise total urinary albumin excretion than Urinary...